ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GNTA
ALGS (20) MGX (23) ESLA (38) EVAX (46) ⌘ Pro Terminal →

Genenta Science S.p.A. (GNTA) — RQD Stock Rating Cockpit

$0.82 +32.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.87

Genenta Science S.p.A. (GNTA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $29.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GNTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Genenta Science S.p.A. (NASDAQ: GNTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.82 (+32.07% 1D, market cap $29.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #268 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GNTA compare to ALGS and MGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and MGX (Metagenomi Therapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $29.5M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GNTA?
▼

For Genenta Science S.p.A. (GNTA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #268 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.87 (+5.58%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510050
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (7)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE GNTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY GNTA SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($834.7K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$0.72-13.9% Next Q
Q2 (-2Q)
45
Grade D$0.62+0% Next Q
Q3 (-1Q)
47
Grade D$0.62+32.3% Next Q
Current
50
Grade D$0.82-1.4% Hist 90D α
Trajectory: D (42) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GNTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GNTA currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.77) and Max Pain ($0.86) forces dealer call-delta covering toward $2.89.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GNTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GNTA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 50%NO 50%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE12% OF RANGE
L: $1$0.82H: $3
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on GNTA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

16/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like GNTA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GNTA)

  • ✓Walkthrough of GNTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GNTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.84%▲ RESISTANCE BREAKOUT
2026-11-03O $0.62H $0.82L $0.62C $0.82VOL 67.2K
RES: $0.46SUP: $0.29SMA50: $0.77SMA200: $1.03
$2.72$2.13$1.54$0.96$0.37RES $0.46SUP $0.29$0.822026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GNTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GNTA Butterfly Map → + Track GNTA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GNTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GNTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GNTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNTA)

Health Care Rank #268 of 1016 ⚔️ ALGS vs GNTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GNTA vs. ALGS, MGX, ESLA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Genenta Science S.p.A. (GNTA) ranks #268 by composite RQD confidence (50/100, grade D) and #798 by equity capitalization ($29.8M). Within this direct 5-issuer industry benchmark cohort, GNTA leads on earnings valuation at N/A trailing P/E, while ALGS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GNTA ACTIVE
Genenta Science S.p.A.
D 50/100 — — — +32.07% $29.8M Benchmark Subject
ALGS
Aligos Therapeutics Inc.
E 20/100 — — -35.0% -4.17% $30.0M /algs-vs-gnta →
MGX
Metagenomi Therapeutics Inc.
E 23/100 — — -35.0% -3.24% $29.5M /mgx-vs-gnta →
ESLA
Estrella Immunopharma Inc.
D- 38/100 — — -35.0% -33.32% $27.8M /esla-vs-gnta →
EVAX
Evaxion A/S
D 46/100 — — — -0.34% $26.4M /evax-vs-gnta →

2. GNTA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Genenta Science S.p.A. (GNTA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $29.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GNTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Genenta Science S.p.A. (NASDAQ: GNTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.82 (+32.07% 1D, market cap $29.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #268 in composite RQD confidence.

How does GNTA compare to ALGS and MGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and MGX (Metagenomi Therapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $29.5M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GNTA?

For Genenta Science S.p.A. (GNTA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #268 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GNTA trading relative to its 50-day, 200-day, and 52-week technical levels?

GNTA last traded at $0.82 (+32.07% on volume of 1,575,058 shares), positioning the stock +6.49% above its 50-day simple moving average ($0.77) and -20.39% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.55 to $2.75, GNTA sits at the 12.3% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.92).

Direct Sub-Reports: GNTA RQD Cockpit GNTA 12M Forecast GNTA Earnings & Move GNTA Dividends & DRIP GNTA Insiders & 13F GNTA Whale Options GNTA Profit Sankey GNTA News & Why
ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ SEC XBRL & RQD VERIFIED

GNTA — Genenta Science S.p.A.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Genenta Science S.p.A. (GNTA) earns a live Roarable RQD composite score of 50/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.82 (+32.07% 1D, market capitalization $29.8M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Genenta Science S.p.A. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. It is classified within this industry with a market capitalization of $0.0B. —: product lines, customer base, and revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 50/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.55 – $2.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), GNTA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can GNTA sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.75 52-week high?
  • Key Question #3: How sensitive is GNTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GNTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Genenta Science S.p.A. (GNTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GNTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GNTA Bull vs. Bear Conversation Board — What's Your Call at $0.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GNTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GNTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.78 (+25.8%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

Long GNTA at $0.62 targeting $0.78. The forensic balance sheet pillar scores 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.. Institutional whale score is 7/20 and the risk/reward vs. the $0.55 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — GNTA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.51 (-17.7%)
Spot @ $0.62

The stock carries a 0% ROIC and 0% FCF yield while facing a Nasdaq minimum bid price deficiency notice, with the RQD verdict set at Und

Here is the bear case nobody on the bull side wants to address on GNTA: The stock carries a 0% ROIC and 0% FCF yield while facing a Nasdaq minimum bid price deficiency notice, with the RQD verdict set at Underperform / Distribution Warning.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%